Matthew Barcus
Stock Analyst at Chardan Capital
(2.47)
# 2,382
Out of 5,129 analysts
21
Total ratings
25%
Success rate
34.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $6.26 | +59.74% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $24.11 | +11.99% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.54 | +1,208.41% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $25.94 | +23.36% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $0.60 | +36,874.79% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.84 | +216.90% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $23.41 | -65.83% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $6.26
Upside: +59.74%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $24.11
Upside: +11.99%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.54
Upside: +1,208.41%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $25.94
Upside: +23.36%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $0.60
Upside: +36,874.79%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.84
Upside: +216.90%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $23.41
Upside: -65.83%